This segment focuses on the research, development, and clinical trials of small molecule therapies for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). The lead product candidate, EDG-5506, is an orally administered small molecule designed to protect muscle fibers from damage in dystrophinopathies. Research and development activities include preclinical studies, Phase 1 and Phase 2 clinical trials, and ongoing efforts to optimize the drug's efficacy and safety profile. The segment utilizes advanced methodologies in drug discovery and development, including precision medicine approaches to target key muscle proteins. The primary goal is to improve the quality of life for patients with DMD and BMD by slowing disease progression and improving muscle function. Market positioning is centered on addressing significant unmet medical needs in rare muscle disorders, with a competitive advantage in its novel mechanism of action. Future opportunities include expanding the clinical program for EDG-5506 and exploring additional indications. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be pursued to accelerate clinical development and commercialization.